4-(7-chloroquinolin-4-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(7-chloroquinolin-4-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
• 英文别名: 7-chloro-4-[4-((4-methoxyphenyl)aminocarbonyl)piperazin-1-yl]quinoline；7-Chloro-4-[4-(4-methoxyphenylaminocarbonyl)piperazin-1-yl]quinoline
• 化学式: C₂₁H₂₁ClN₄O₂
• 分子量: 396.876
• InChiKey: SOJIKBIURBRJFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,7-二氯喹啉 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 4-(7-chloroquinolin-4-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
  参考文献：
  名称：

  Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors

  摘要：

  A structure based medium throughput virtual screening campaign of BITS-Pilani in house chemical library to identify novel binders of Mycobacterium tuberculosis gyrase ATPase domain led to the discovery of a quinoline scaffold. Further medicinal chemistry explorations on the right hand core of the early hit, engendered a potent lead demonstrating superior efficacy both in the enzyme and whole cell screening assay. The binding affinity shown at the enzyme level was further corroborated by biophysical characterization techniques. Early pharmacokinetic evaluation of the optimized analogue was encouraging and provides interesting potential for further optimization. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.06.042

文献信息

• [EN] SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CCR5 A BASE DE QUINOLEINE SUBSTITUES
  申请人：SCHERING AG

  公开号：WO2004002960A1

  公开（公告）日：2004-01-08

  The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

  本发明涉及式（1a）或（1b）的CCR5受体拮抗剂，其对映体、二对映体、盐和溶剂合物，其中R1、R2、R3、R4、R5和R7如本文所定义。该发明还包括一种利用这些化合物治疗CCR5介导的疾病的方法。
• Substituted quinoline CCR5 receptor antagonists
  申请人：Schering Aktiengesellschaft

  公开号：US20040072818A1

  公开（公告）日：2004-04-15

  The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): 1 enantiomers, diastereomers, salts and solvates thereof wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

  本发明涉及公式（1a）或（1b）的CCR5受体拮抗剂：1对映体，对异构体，其盐和溶剂化物，其中R1、R2、R3、R4、R5和R7如本文所定义。本发明还包括一种利用这些化合物治疗CCR5介导的疾病的方法。
• SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP1534681A1

  公开（公告）日：2005-06-01
• US7220856B2
  申请人：——

  公开号：US7220856B2

  公开（公告）日：2007-05-22
• Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors
  作者：Variam Ullas Jeankumar、Rudraraju Srilakshmi Reshma、Rahul Vats、Renuka Janupally、Shalini Saxena、Perumal Yogeeswari、Dharmarajan Sriram

  DOI：10.1016/j.ejmech.2016.06.042

  日期：2016.10

  A structure based medium throughput virtual screening campaign of BITS-Pilani in house chemical library to identify novel binders of Mycobacterium tuberculosis gyrase ATPase domain led to the discovery of a quinoline scaffold. Further medicinal chemistry explorations on the right hand core of the early hit, engendered a potent lead demonstrating superior efficacy both in the enzyme and whole cell screening assay. The binding affinity shown at the enzyme level was further corroborated by biophysical characterization techniques. Early pharmacokinetic evaluation of the optimized analogue was encouraging and provides interesting potential for further optimization. (C) 2016 Elsevier Masson SAS. All rights reserved.